Foto

HedgePath Pharmaceuticals (HPPI) versus Iqvia (IQV) Head-To-Head Review

HedgePath Pharmaceuticals ( OTCMKTS:HPPI ) and Iqvia ( NYSE:IQV ) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, profitability and earnings.

Valuation & Earnings

Get HedgePath Pharmaceuticals alerts: This table compares HedgePath Pharmaceuticals and Iqvia’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HedgePath Pharmaceuticals N/A N/A -$4.55 million N/A N/A Iqvia $10.41 million 2,741.63 $259.00 million $5.12 28.18 Iqvia has higher revenue and earnings than HedgePath Pharmaceuticals.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for HedgePath Pharmaceuticals and Iqvia, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HedgePath Pharmaceuticals 0 0 0 0 N/A Iqvia 0 3 12 2 2.94 Iqvia has a consensus price target of $147.20, suggesting a potential upside of 2.02%. Given Iqvia’s higher probable upside, analysts clearly believe Iqvia is more favorable than HedgePath Pharmaceuticals.

Profitability

This table compares HedgePath Pharmaceuticals and Iqvia’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets HedgePath Pharmaceuticals N/A N/A -293.13% Iqvia 2.49% 14.25% 4.78% Institutional & Insider Ownership

91.0% of Iqvia shares are held by institutional investors. 4.3% of HedgePath Pharmaceuticals shares are held by company insiders. Comparatively, 6.0% of Iqvia shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

HedgePath Pharmaceuticals has a beta of -1.04, suggesting that its share price is 204% less volatile than the S&P 500. Comparatively, Iqvia has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500.

Summary

Iqvia beats HedgePath Pharmaceuticals on 11 of the 11 factors compared between the two stocks.

HedgePath Pharmaceuticals Company Profile

HedgePath Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for patients with cancers in the United States. It primarily focuses on the development of therapies for skin, lung, and prostate cancers. The company's Hedgehog signaling pathway is a primary regulator of cellular processes in vertebrates, including stem cell maintenance, cell differentiation, tissue polarity, and cell proliferation. It is conducting an open-label Phase II (b) clinical trial for studying the effect of SUBA-Itraconazole oral capsules in patients with basal cell carcinoma nevus syndrome. SUBA-Itraconazole is a patented and proprietary itraconazole formulation that enhances the absorption of itraconazole to enhance the bioavailability of orally administered drugs that are poorly soluble. The company was founded in 1992 and is headquartered in Tampa, Florida.

Iqvia Company Profile

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order to life science companies, and investment and financial sectors that deal with life science companies; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level to pharmaceutical sales organizations. The Research & Development Solutions segment offers biopharmaceutical development services comprising project management and clinical monitoring, clinical trial support, and strategic planning and design services, as well as clinical trial, genomic, and bioanalytical laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.